Homologous Recombination Pathway Panels Market Report 2026

Homologous Recombination Pathway Panels Market Overview

• Homologous Recombination Pathway Panels market size has reached to $1.12 billion in 2025 • Expected to grow to $2.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.7% • Growth Driver: Rising Adoption Of Targeted Therapies Driving Growth In The Market Due To Increasing Demand For Precision Medicine And Personalized Treatment • Market Trend: Innovations In Homologous Recombination Pathway Panel Technologies Enhance Precision Oncology And Biomarker Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Homologous Recombination Pathway Panels Market?

Homologous recombination pathway panels refer to specialized genetic testing panels that analyze a set of genes involved in the homologous recombination (HR) DNA repair pathway, which is responsible for accurately repairing double-strand breaks in DNA to maintain genomic stability. These panels are widely used in cancer diagnostics, hereditary cancer risk assessment, and precision oncology to detect mutations that can influence cancer susceptibility, prognosis, and response to targeted therapies such as poly ADP ribose polymerase inhibitors. The main panel types of homologous recombination pathway panels include comprehensive homologous recombination deficiency panels, focused or core homologous recombination repair gene panels, custom or research panels, and integrated genomic profiling kits. Comprehensive homologous recombination deficiency panels refer to panels designed to detect deficiencies in homologous recombination repair pathways for research and clinical purposes. These panels utilize technologies such as next-generation sequencing, polymerase chain reaction, microarray based panels, and other molecular diagnostic techniques. The applications include cancer research, genetic disorder studies, drug discovery, clinical diagnostics, and other applications, and the end users are hospitals and clinics, diagnostic laboratories, research institutes, biotechnology companies, and pharmaceutical companies.

What Is The Homologous Recombination Pathway Panels Market Growth Forecast?

The homologous recombination pathway panels market size is expected to see rapid growth in the next few years. It will grow to $2.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to increasing adoption of companion diagnostics, rising demand for personalized cancer therapies, expansion of clinical genomics in hospitals, growing use of AI-driven variant interpretation, increasing regulatory approvals for genomic panels. Major trends in the forecast period include increasing adoption of comprehensive hrd testing panels, rising use of ngs-based homologous recombination assays, growing demand for therapy-selection focused panels, expansion of integrated genomic profiling kits, enhanced focus on rapid turnaround diagnostic panels.

Global Homologous Recombination Pathway Panels Market Segmentation

1) By Panel Type: Comprehensive Homologous Recombination Deficiency Panels; Focused Or Core Homologous Recombination Repair Gene Panels; Custom Or Research Panels; Integrated Genomic Profiling Kits 2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Microarray Based Panels; Other Molecular Diagnostic Techniques 3) By Application: Cancer Research; Genetic Disorder Studies; Drug Discovery; Clinical Diagnostics; Other Applications 4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Biotechnology Companies; Pharmaceutical Companies Subsegments: 1) By Comprehensive Homologous Recombination Deficiency Panels: Broad Gene Coverage Panels; Clinical Grade Diagnostic Panels; Therapy Selection Panels; Prognostic Risk Assessment Panels 2) By Focused Or Core Homologous Recombination Repair Gene Panels: Single Pathway Targeted Panels; Small Gene Set Panels; Cost Optimized Clinical Panels; Rapid Turnaround Testing Panels 3) By Custom Or Research Panels: Disease Specific Research Panels; Institution Designed Gene Panels; Exploratory Genomic Study Panels; Preclinical Research Panels 4) By Integrated Genomic Profiling Kits: Multigene Sequencing Kits; Combined Mutation And Structural Variant Kits; End To End Genomic Analysis Kits; Clinical Workflow Integrated Kits

What Are The Drivers Of The Homologous Recombination Pathway Panels Market?

The increasing adoption of targeted therapies is expected to drive the growth of the homologous recombination pathway panels market going forward. Targeted therapies are treatments designed to specifically target disease-causing molecules or genetic abnormalities in cells, inhibiting their growth while minimizing damage to normal cells. The rising use of targeted therapies is fueling demand for precision medicine, as patients and healthcare providers prefer treatments that are more effective and have fewer side effects compared to conventional therapies. Homologous recombination (HR) pathway panels support targeted therapies by identifying patients likely to respond to DNA damage–targeting drugs, enabling clinicians to tailor treatment plans and enhance therapeutic outcomes. For instance, in July 2023, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Hence, the growing adoption of targeted therapies is propelling the expansion of the homologous recombination pathway panels industry. The rising number of clinical trials is expected to propel the growth of the homologous recombination pathway panels market going forward. Clinical trials are controlled research studies conducted in humans to evaluate the safety and efficacy of medical interventions. The increase in clinical trials is driven by the growing prevalence of chronic and complex diseases, which creates a demand for novel and effective treatments. Clinical trials support homologous recombination pathway (HRP) panels by validating their ability to detect patients with HR gene defects, guiding targeted therapies, and evaluating treatment outcomes in real-world patient populations. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the number of industry clinical trials initiated in the UK increased to 426 in 2023, from 411 in 2022. Thus, the expanding number of clinical trials is fueling the growth of the homologous recombination pathway panels industry.

Key Players In The Global Homologous Recombination Pathway Panels Market

Major companies operating in the homologous recombination pathway panels market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Integrated DNA Technologies Inc., NeoGenomics Laboratories Inc., Promega Corporation, Invitae Corporation, Caris Life Sciences Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Metropolis Healthcare Limited, AmoyDx Diagnostics Co. Ltd., CD Genomics, iGeneTech Inc., and Paragon Genomics Inc.

Global Homologous Recombination Pathway Panels Market Trends and Insights

Major companies operating in the homologous recombination pathway panels market are focusing on developing advanced comprehensive genomic profiling solutions to identify DNA repair deficiencies, guide targeted therapies, and enable personalized treatment strategies for cancer patients. Comprehensive genomic profiling refers to an advanced testing approach that examines hundreds of genes simultaneously to identify genetic alterations, biomarkers, and molecular signatures, enabling precision medicine and informed therapeutic strategies. For instance, in September 2024, Integrated DNA Technologies, a US-based biotechnology company, launched Archer homologous recombination deficiency (HRD) technology to detect homologous recombination deficiencies and guide targeted cancer therapies. These technologies assess homologous recombination deficiency (HRD) in solid tumors to enhance comprehensive genomic profiling (CGP) for cancer research. Its purpose is to detect key biomarkers such as HRD alongside MSI and TMB from low-input samples, supporting precision medicine via flexible NGS panels without workflow overhauls. Advantages include AMP chemistry for standalone, spike-in, or integrated use, optimizing resources and customization.

nan

Regional Insights

North America was the largest region in the homologous recombination pathway panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Homologous Recombination Pathway Panels Market?

The homologous recombination pathway panels market consists of sales of the homologous recombination deficiency complete panels, the handle homologous recombination repair next-generation sequencing panels, homologous recombination deficiency focus panels, breast cancer susceptibility gene research assays, homologous recombination repair pathway predesigned panels, and the comprehensive assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Homologous Recombination Pathway Panels Market Report 2026?

The homologous recombination pathway panels market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the homologous recombination pathway panels industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.